Opening book details…
About this Medicine article
357PPatient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease by Ettl, J; Quek, R G W; Bhattacharyya, H; Rugo, H S; Hurvitz, S A; Gonçalves, A is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Ettl, J; Quek, R G W; Bhattacharyya, H; Rugo, H S; Hurvitz, S A; Gonçalves, A
- Publisher
- Oxford University Press; Elsevier BV (ISSN 0923-7534)
- Published
- 2019
- Field
- Medicine (Health Sciences)
More by Ettl, J; Quek, R G W; Bhattacharyya, H; Rugo, H S; Hurvitz, S A; Gonçalves, A
Browse all works by Ettl, J; Quek, R G W; Bhattacharyya, H; Rugo, H S; Hurvitz, S A; Gonçalves, A